21657
document
Comparative study of the efficacy of eprinomectin versus ivermectin , and field efficacy of eprinomectin only , for the treatment of chorioptic mange in alpacas . The efficacy of eprinomectin versus ivermectin ( Study 1 : a single-centre , randomised , treatment-controlled , blinded field trial ) , and the field efficacy of eprinomectin ( Study 2 : a single-centre , open , un-controlled field trial ) for the treatment of chorioptic infestation in naturally infested alpacas were assessed in two studies . Thirty alpacas , all positive for Chorioptes sp . mite , were randomly allocated to two treatment groups in Study 1 . Group A received a single topical administration of a 0.5 % formulation of eprinomectin at the dose rate of 500mug/kg . Group B received three subcutaneous administrations at 14 days interval of a 1 % formulation of ivermectin at the dose rate of 400mug/kg . Response to treatment was assessed by periodic mite count , and skin lesions scored . In Study 2 , one group of 19 alpacas received four administrations at weekly interval of topical eprinomectin at the dose rate of 500mug/kg , and response to treatment was monitored by mite counts . No localised or systemic side effects were observed in either trial . There was a statistically significant decrease in mite counts on day 7 ( P < 0.001 ) within treatment Groups A and B of Study 1 , but mite counts increased again on day 14 and remained high for the duration of the trial in both treatment groups . On day 14 of Study 2 , there was a statistically significant reduction in mite counts ( P < 0.008 ) and the mite counts remained very low throughout the remainder of the study . The eprinomectin protocol employed in Study 2 , consisting of four weekly topical administrations at the dose rate of 500mug/kg of body weight , proved highly effective at reducing the Chorioptes mite burden in alpacas .
21658
Intervention_Pharmacological
eprinomectin
21659
Intervention_Pharmacological
ivermectin
21660
Intervention_Pharmacological
eprinomectin
21661
Intervention_Pharmacological
eprinomectin
21662
Intervention_Pharmacological
ivermectin
21663
Intervention_Pharmacological
eprinomectin
21664
Intervention_Pharmacological
eprinomectin
21665
Intervention_Pharmacological
ivermectin
21666
Intervention_Pharmacological
eprinomectin
21667
Intervention_Pharmacological
eprinomectin
21668
Outcome_Other
efficacy
21669
Outcome_Other
field efficacy
21670
Outcome_Other
efficacy
21671
Outcome_Other
field efficacy
21672
Outcome_Physical
Response to treatment
21673
Outcome_Physical
periodic mite count
21674
Outcome_Physical
skin lesions scored
21675
Outcome_Physical
mite counts
21676
Outcome_Adverse-effects
localised or systemic side effects
21677
Outcome_Physical
mite counts
21678
Outcome_Other
mite counts
21679
Outcome_Physical
mite counts
21680
Outcome_Physical
mite counts
21681
Outcome_Other
Chorioptes mite burden
21682
Participant_Condition
chorioptic mange
21683
Participant_Sample-size
Thirty
21684
Participant_Sample-size
19
21685
Participant_Condition
Chorioptes mite burden